Infection with human immunodeficiency virus (HIV) may lead to hemostatic imbalances. Forty-nine consecutive patients with acute opportunistic infections were screened for thrombophilic parameters. A follow-up investigation was performed after 10 ± 8 weeks in 26 patients. In acutely ill patients, the incidence of protein S deficiency was 67% (33/49) and of protein C deficiency 25% (12/49), while at the follow-up visit the incidences were 54% (14/26) and 8% (2/26), respectively. Protein S and protein C levels increased significantly from initial to follow-up visit (p < 0.05). Lupus anticoagulants
Protein C and protein S are important physiologic coagulation inhibitors. While both proteins are synthesized by hepatocytes in the presence of vitamin K, protein S additionally is produced by endothelial cells and megakaryocytes (1) . Thirty percent to 40% of protein S circulates free and 60% to 70% is bound to C4b-binding protein (C4b-BP) (2) . Only free protein S is functionally active as a cofactor for activated protein C (2) . The inactive form of protein C is activated by the thrombin-thrombomodulin complex, which converts protein C to activated protein C (APC). APC then interacts with its cofactor protein S on phospholipid surfaces and inactivates factor V and factor VIII by proteolysis (2) . Hereditary protein C and protein S deficiencies are thus associated with an increased risk for venous thromboembolic complications (3, 4) . The incidence of congenital protein C and protein S deficiency in the general population varies between 0.003% and 0.004% (5) , while protein C and protein S deficiency is found in 1.5% to 3% of patients with thromboembolic disease (4, 6, 7) . These thromboembolic complications often occur at a young age in the presence of additional predisposing factors. Common causes for acquired protein C and protein S deficiencies are disturbed liver function (8) , low levels of vitamin K, disseminated intravascular coagulation (8), consumption in acute thrombosis (5, 8) , and in human immunodeficiency virus (HIV) infection (9, 10) . An additional acquired decrease in protein S levels occurs during pregnancy, with the use of oral contraceptives, in nephrotic syndrome, and in systemic autoimmune disease (11, 12) . Protein S deficiency in HIV-infected patients is detected in 27% to 76% (10, (13) (14) (15) (16) (17) , while protein C deficiency is detected in 0% to 14% of patients (10, (14) (15) (16) . Studies on the correlation of protein S and protein C activity with the CD4+ T-lymphocyte count are inconclusive at present (9, 10, (13) (14) (15) . The cause of these acquired coagulation inhibitor deficiencies in HIV-infected patients remains unknown, but the decrease of protein S and protein C levels may be induced by acute opportunistic infections.
We therefore investigated the incidence of acquired deficiencies of protein S and protein C in HIV patients with acute disease and performed a follow-up investigation after discharge from hospital. Clinical symptoms of thromboembolism were also documented.
PATIENT POPULATION
HIV-infected patients admitted to the university hospital in Frankfurt were only included in the investigation, when the following inclusion criteria were fulfilled:
1. Aspartate aminotransferase (AST) < 130 U/L, alanine aminotransferase (ALAT) < 130 U/L, prothrombin time (PT) ratio < 1.3.
No acute liver disease.
Between May 1998 and June 1999, 49 consecutive seropositive HIV-infected patients were included, while 52 patients had to be excluded because of clinically relevant liver disease. All patients had been admitted to hospital for opportunistic infections or concomitant disorders ( Table 1 ). The mean age of included patients (39 men and 10 women) was 39 years (range, 18-62 years). All patients were evaluated for PT, activated partial thromboplastin time (aPTT), protein C and protein S activity, antithrombin activity, activated protein C resistance (APC-R), diluted Russel's viper venom time (DRVVT), anticardiolipin IgG and IgM antibodies, C-reactive protein (CRP), leukocyte count, ALAT, ASAT, GLDH, cholinesterase (CHE), CD4+ T-lymphocyte counts, and HIV-RNA-PCR, respectively. Follow-up evaluation 10 + 8 weeks after the first evaluation was performed in 26 patients, all of whom were patients of the HIV outclinic department.
Seventy-four percent of the patients (36/49) had a CD4 count < 200/,L with an average total virus load of 366 x 103 copies/mL, while 26% of the patients (13/49) had CD4 counts of . 200/4L with an average total virus load of 142 x 103 copies/mL. On admission, 20/49 (41%) of the patients were treated with antiretroviral therapy. 
METHODS
Blood was collected by venipuncture using 3.8% trisodium citrate as anticoagulant. The samples were centrifuged at 2000 g for 15 minutes at room temperature, and stored at -70°C until used for testing. The following coagulation tests were performed on a STA coagulation analyzer (Roche Diagnostics, Mannheim, Germany):
PT: Neoplastin Plus®, normal range: 70% to 100%; APTT: PTT LT, normal range: 27 to 40 seconds; thrombin time (TT): STA Thrombin reagent, thrombin concentration 1.5 NIMH/mL, normal range: 15 to 20 seconds; protein S activity: Asserachrom STA Protein S clotting, which is insensitive to APC resistance, normal range for men: 74% to 155%, for women: 60% to 140%; protein C activity: Coamatic LR (Haemochrom Diagnostics Essen, Germany), normal range: 70% to 146%; antithrombin activity: Coamatic LR (Haemochrom Diagnostics Essen, Germany), normal range: 85% to 120%; APC-R: COATEST APC Resistence V with factor V-deficient plasma, normal range: 2.0 to 3.0 (Chromogenix, Milano, Italy).
In addition the following ELISA assays were performed:
Anticardiolipin IgM and IgG antibodies: anticardiolipin IgG/IgM (Orgentec, Diagnostica GmbH, Mainz, Germany), normal range for anticardiolipin IgM: 0.5 to 7.0 U/mL, for anti-cardiolipin IgG: 0.5 to 10.0 U/mL; anti-f2 glycoprotein I IgM and IgG antibodies: anti-,B2 glycoprotein I IgG/IgM (Orgentec, Diagnostica GmbH, Mainz, Germany), normal range for anti-P2 glycoprotein I 1gM antibodies: 0.5 to 8.0 U/mL, for anti-j2 glycoprotein I IgG antibodies: 0.5 to 8.0 U/mL; DRVVT assay: LAC screen and Lac confirm (Instrumentation Laboratory, Milano, Italy), normal range for Lac screen: 30.6 to 39.9 seconds, Lac confirm: 30.4 to 35.6 seconds, for ratio Lac screen / Lac confirm: 0.9 to 1.3. Virus load (VL): Roche-Amplicor HIV-PCR, normal range: not detectable (Roche Diagnostics, Mannheim, Germany). Suspected venous thrombosis was confirmed by color coded duplex scan with an Acuson 128 XP/1OM.
STATISTICS
Statistical analysis was performed using SPSS statistical software (SPSS version 6.12; SPSS, Chicago, IL). Parameters were assessed for Gaussian distribution using the Kolmogorov-Smirnov test. Additionally the following tests for nonparametric parameters were used: Spearmann's rank correlation coefficient was used to assess correlation between CD4+ T-lymphocytes, VL, anticardiolipin IgG. anticardiolipin IgM. CRP, antithrombin, PT, protein S, and protein C. Mann-Whitney U-Wilcoxon rank sum test was used for comparison of first and follow-up visit concerning CRP, VL, and CD4+ T-lymphocyte count. The comparison of protein S and protein C levels in patients with thromboembolic complications was performed by the Mann Whitney Utest. For parametric parameters, the following tests were used: t test for paired samples was used to compare means of protein S and protein C levels at first and follow-up visit. Students t test for unpaired samples was used to compare differences between protein S and protein C and CD4+ T-lymphocyte levels. P values equal or less than 0.05 were considered significant. Table 2 shows the mean values of protein S and protein C activity in 49 patients at their initial visit. No significant differences were found between patients with CD4+ < 200/,u and patients with CD4+ . 200/AL, respectively.
RESULTS
The incidence of protein S deficiency at the first visit was 67% (33/49). Protein C deficiency was observed in 25% (12/49). Concerning protein S and protein C activity, a positive correlation between protein C activity and antithrombin (p < 0.001) and with PT (p < 0.01) was observed at the first visit, while a negative correlation was seen with CRP (p < 0.05). No correlation was found between ALAT, ASAT and protein S or protein C activity. Twenty-six patients were studied at a follow-up investigation 10 + 8 weeks after the first evaluation. In 14/26 patients (54%), protein S deficiency was observed at the follow-up visit compared to 19/26 patients (73%) at the initial visit (p = 0.267); 2/26 (8%) of the patients had protein C deficiency at the follow-up visit compared to 4/26 (15%) of patients at the initial visit (p = 0.625). Compared to the first visit, protein S and protein C activity increased significantly at the follow-up visit (PS: 56.6% vs. 74.3%; p = 0.011, PC: 81.5% vs. 99.4%; p = 0.012; see Fig. 1 ). While a significant decrease in CRP ( 6.9 mg/dL vs. 1.9 mg/dL, p < 0.05) and VL (385,158/nL vs. 144,572/nL, p < 0.05) was observed, a significant increase in CD4+ T-lymphocytes (107/,L vs. 151/,uL, p < 0.05) was also seen (Table 3 ). Anticardiolipin IgG was detected in 11.4% (5/44) and anticardiolipin IgM in 4.7% (2/43) of the patients. No correlation to low protein S or protein C levels was observed. Lupus anticoagulants were not detected.
On admission or during hospitalization, 6/49 (12%) patients had thromboembolic complications (TE) ( Table 4 ). Three patients presented with DVT and one with a severe thrombophlebitis. After discharge, in one patient, DVT developed in the other leg after 14 weeks. Two patients with heart failure presented with a thrombus of the right ventricle, diagnosed with echocardiography.
Five of the six patients with TE had protein S or protein C deficiency. No additional predisposing factors or a positive family history of TE were identified. APC-R, lupus anticoagulants, and anticardiolipin antibodies were negative in all patients with TE.
Patients with thromboembolic complications had lower levels of protein S or protein C activity than patients without thromboembolic complications (Table 5 ). No relevant changes concerning PT, PTT, or TT were observed.
DISCUSSION
The incidence of congenital protein C and protein S deficiency in the general population and the incidence of acquired protein S and C deficiency in patients with inflammatory syndromes without HIV infection (18) is low. We observed a high incidence of protein S deficiency (67%) and protein C deficiency (25%) in HIV-infected patients.
The high proportion of patients with protein S deficiency may be due to the acute illness, an observation reported by other studies (13, 14, 16, 19) , while in studies with HIV patients in good physical condition, protein S deficiency was only observed in 20% to 31% of patients (9, 17, 20) . Corresponding results were found concerning protein C deficiency, which is also more pronounced in sick HIV patients compared to HIV patients in good physical condition (13) .
The significant increase of protein S and protein C activity after discharge may therefore be explained by the antiretroviral treatment and the treatment of the opportunistic infections (9, 14, 19) . These findings may explain the in- Results are given as mean ± SD. VLlog, total virus load shown as logarithm. creased risk of thrombosis among HIV infected patients observed by Sullivan and associates (21) . In case of inflammation, C4b-BP, as an acute phase reactant, increases (5, 18) . This can lead to a temporary reduction in free protein S antigen and protein S activity (5, 10) . Boullanger and associates (18) however did not observe a decrease of free protein S in inflammatory syndromes other than HIV even though C4b-BP was increased. He demonstrated, that a higher level of C4b-binding protein did not reduce the level of free protein S. No deficiency for protein S and protein C was found in patients with inflammatory bowel disease (18, 22) , while even an increase of protein S and protein C activity in these patients has been observed (23) . Therefore, un- specific inflammatory syndromes may not induce an acquired protein C and protein S deficiency, while protein S deficiency induced by HIV disease results in decreased free and total protein S antigen levels, but normal C4b-BP levels, suggesting that these changes may be different to those occuring in unspecific inflammation (9) . In contrast to some studies (13, 14) we did not observe a significant difference concerning protein S and protein C deficiency in patients with low (< 200/pL) or high CD4+ T-lymphocyte counts (> 200/pt), an observation that was also confirmed in other studies (9, 10, 15) .
Malia and associates postulated that antiphospholipid antibodies may interfere with the activated protein C/protein S complex at the phospholipid surface (24) and therefore may lead to protein S deficiency. Some authors (14, 19, 25) detected high levels (5% to 93%) of antiphospholipid antibodies in HIV-infected patients, which may explain the low levels of protein S activity. In contrast, the incidence of antiphospholipid antibodies in our population was only 11.4% (5/44) for anticardiolipin IgG and 4.7% (2/43) for anticardiolipin IgM without any correlation to low protein S levels, a finding that was also reported by Lafeuillade and associates (17) .
Other reports have also linked protein S deficiency to the presence of lupus anticoagulants (26) , suggesting that protein S binds to antiphospholipid antibodies. This finding was not confirmed in our study because no lupus anticoagulants were observed. These conflicting results may be due to the different assay systems used for diagnosing antiphospholipid antibodies and lupus anticoagulants. In fact, antiphospholipid antibodies have been shown to be polyspecific and cross-react with other anionic phospholipids (27, 28) . Many of the HIV-infected patients have hypergammaglobinemia with high IgG levels. It is likely, that elevated anticardiolipin antibody levels in such patients may simply reflect a nonspecific increase in immunoglobulin production (24) .
While the incidence of DVT in the normal population is low (0.08% to 0.12%) (29), we found an increased incidence of DVT in our HIV population (6.1%, 3/49). A similar incidence of TE was observed by Bissuel and associates (5%, 3/63) (14) , while Sorice and coworkers (15) did not detect any thromboembolic complications (0%, 0/23). In a multicenter survey, Sullivan and associates (21) retrospectively reported a high incidence of DVT in 42,935 HIV-infected patients (0.64%) compared to the normal population. Patients with TE on admission or during hospitalization had lower levels of protein S or protein C activity than patients without TE, but the differences were not significant because of the small number of patients. Prospective trials with large numbers of patients are needed to clarify the clinical relevance of these laboratory findings.
In conclusion, protein S and protein C deficiency often develops in HIV-infected patients hospitalized for opportunistic infections or other acute illnesses. With improvement of the underlying condition, a significant increase of protein C and protein S levels is observed. The clinical relevance of these findings and their impact on the risk of thromboembolic complications remains unknown. When HIV patients with thromboembolic complications are screened for thrombophilic defects, the high incidence of acquired protein S and protein C deficiency in this patient population has to be taken into account.
